Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan's Eisai, Takeda And Shionogi Look To Accelerate Weight Loss Drug Development

This article was originally published in PharmAsia News

Executive Summary

Major Japanese drug companies Eisai and Takeda are looking to accelerate commercialization of weight loss drugs for metabolic syndrome. Eisai's anti-obesity agent KES524 (sibutramine), licensed from Abbott Laboratories, is pending approval in Japan. Takeda's therapeutic diet agent ATL-962 (cetilistat) is in Phase III clinical development in Japan. Takeda obtained the exclusive rights from U.K. biotech Alizyme. Shionogi also plans a Phase I trial for S-2367 by the end of this September. S-2367 is at Phase II development in the U.S. Other Japanese drug makers are developing over-the-counter obesity drugs. Taisho Pharmaceutical obtained exclusive rights to Alli (oristat) from GlaxoSmithKline in January. Kobayashi Pharmaceutical launched traditional Chinese medicine Beslight Gold a targeting middle-aged females and Naisitoru85 targeting male customers. Marketing firm Fuji Keizai estimated a 4 percent increase to ¥12 billion for the obesity drug market in 2009. (Click here for more - Japanese language

You may also be interested in...

Coronavirus Update: Novartis Joins Antiviral Therapies Search With Novel DARPin Alliance

Swiss biotech Molecular Partners will receive upfront payment of CHF 60m, including equity.

Experts Call For Unifying Measures For EU Political And Regulatory Oversight

Just as the MDR and IVDR are being implemented, increasing regulatory divergence in Europe is a growing danger to patient safety throughout the EU, not least through increasing costs and impacting device availability.

IVDR Implementation Not Yet On Track: What The Diagnostics Sector Needs To Do

It’s time to focus on how the diagnostics sector will comply with the EU’s IVD Regulation. TÜV SÜD expert, Andreas Stange, explains why the IVD industry could be in trouble and what must be done now.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts